Sign Out
ATC code: A10AE.
Pharmacology: Pharmacodynamics: Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein and fats. Target organs for insulin include the liver, skeletal muscle and adipose tissue.
Within the liver: insulin stimulates hepatic glycogen synthesis.
Pharmacokinetics: Onset of action: 3 to 4 hours.
Duration: 10.8 to > 24 hours.
Absorption: Slow.
Metabolism: Partially metabolized in the subcutaneous depot at the carboxyl terminus of the B chain to form two active metabolites, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin).
Time to peak, plasma: No pronounced peak; Excretion: Urine.
Toxicology: Preclinical safety data: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
However, there is a risk of malignant fibrous histiocytoma shown in a non-clinical study of Gansulog.
